Blogs
4 key trends changing the access landscape through to 2025
By Jens Leutloff, Senior Consultant Email: [email protected] Partners4Access asked payer experts from France, Germany, Italy, Spain, and the Nordics what the key trends are for
HTA and pricing update: Recent moves on drug cost-control by European payers
By Chloe Sheppard, Analyst Email: [email protected] The issue of affordability and access to medicines has been brought to the forefront of policymakers’ and payers’ attention
Trump finally signs executive order on Medicare drug pricing but will anything change on the ground?
By Max Rex, Consultant Email: [email protected] After years of rhetoric about drug pricing, President Trump signed an executive order on Sunday 13th September which aims
Driving patient access for treatments targeting rare genetic disorders in the Middle East
By Ciaran Cassidy, S Analyst Email: [email protected] At the World Orphan Drug Conference (WODC) this year Dr Maryam Matar presented on the success of the
Under the microscope: Orphan Drug incentives in Europe
By Chloe Sheppard, Analyst Email: [email protected] The European Commission is imminently expected to publish a report evaluating the pros and cons of the EU Orphan
France to place restrictions on Nominative ATU
By Erfan Akbraian, Analyst Email: [email protected] France’s National Agency for the Safety of Medicines and Health Products (ANSM)1 governs the early access program called autorisation
Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?
By Max Rex, Associate Consultant Email: [email protected] Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green
Cancelled meetings and assessment delays: HTA bodies are revising priorities in response to COVID-19
By Nicola Allen, Associate Director Email: [email protected] The priorities of health technology assessment (HTA) bodies are evolving as health care systems around the world are
Deadline day approaches for Israel’s market entry hopefuls
By Erfan Akbraian, Analyst Email: [email protected] Majority of orphan drug manufacturers do not currently view Israel as an early launch opportunity. However, universal reimbursed access
